Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    RGX-202

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Regenxbio Hits Duchenne Milestone, Eyes 2027 FDA Approval
    Regenxbio Hits Duchenne Milestone, Eyes 2027 FDA Approval

    14 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/regenxbio-slumps-after-serious-side-effects-mar-Duchenne-gene therapy-results

    BIOSPACE
    14 May 2026
    Share Share
    REGENXBIO to Present at ASGCT 2026 Annual Meeting
    REGENXBIO to Present at ASGCT 2026 Annual Meeting

    07 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene--cell-therapy-2026-annual-meeting-302765129.html

    PR NEWSWIRE
    07 May 2026
    Share Share
    Regenxbio Gene Therapy Passes Interim Test As Pivotal Data Loom
    Regenxbio Gene Therapy Passes Interim Test As Pivotal Data Loom

    12 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/regenxbio-posts-clean-safety-profile-dmd-gene-therapy-pivotal-data-loom

    FIERCE BIOTECH
    12 Mar 2026
    Share Share
    Regenxbio Unveils Positive Interim Data from RGX-202 Phase I/II
    Regenxbio Unveils Positive Interim Data from RGX-202 Phase I/II

    11 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-reports-new-positive-interim-data-from-phase-iii-affinity-duchenne-trial-of-rgx-202-302711193.html

    PR NEWSWIRE
    11 Mar 2026
    Share Share
    REGENXBIO Presents At 2026 (MDA) Clinical & Scientific Conference
    REGENXBIO Presents At 2026 (MDA) Clinical & Scientific Conference

    04 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2026-muscular-dystrophy-association-mda-clinical--scientific-conference-302703477.html

    PR NEWSWIRE
    04 Mar 2026
    Share Share
    REGENXBIO Completes Pivotal Enrollment, Duchenne Gene Therapy
    REGENXBIO Completes Pivotal Enrollment, Duchenne Gene Therapy

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-pivotal-enrollment-and-initiates-commercial-production-in-duchenne-gene-therapy-program-302599520.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.